Compare IHD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | GNLX |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 202.4M |
| IPO Year | N/A | 2023 |
| Metric | IHD | GNLX |
|---|---|---|
| Price | $6.75 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 27.7K | ★ 377.3K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.49 | $1.99 |
| 52 Week High | $5.47 | $8.54 |
| Indicator | IHD | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 29.26 |
| Support Level | $6.76 | $2.61 |
| Resistance Level | $7.09 | $2.97 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 19.97 | 6.15 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.